Motor symptoms, ‘off’ time improve in Phase 1 Bemdaneprocel trial
Treatment with the cell therapy bemdaneprocel (BRT-DA01) led to reductions in motor symptom severity for people with Parkinson’s disease in a small clinical trial, according to data announced by BlueRock Therapeutics, its developer. “We are
